HASTINGS PAUL J sold $5K of NKTX

HASTINGS PAUL J (Chief Executive Officer) sold 1,776 shares of Nkarta, Inc. (NKTX) at $2.71 on 2026-06-18.

Original reporting
SEC EDGAR · HASTINGS PAUL J
Published Jun 22, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NKTX
Neutral
low confidence
Mentioned
$NKTX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NKTXNeutralLow
01

Why it matters

The newest fact is the CEO’s open-market sale details (shares, price, total value, and post-transaction holdings). This can marginally affect sentiment but does not introduce new company fundamentals.

02

Market read

Traders may monitor insider activity for sentiment, but this specific disclosure lacks a fundamental trigger and is unlikely to drive sustained repricing.

03

What to watch

No 10b5-1 plan is stated, but the article does not provide context on prior sales, compensation timing, tax events, or whether other insiders sold/bought around the same period.

Relevance 3/10Novelty 3/10Timing: Filed June 22, covering a sale dated June 18.

Background

The article is an SEC Form 4 insider transaction disclosure for Nkarta, Inc. (NKTX).

Company-level read

Ticker impact

$NKTXNeutralLow confidence
Context

Nkarta CEO Paul J Hastings sold 1,776 shares in an open-market transaction at $2.71 per share, per a newly filed Form 4.

Expected impact

Likely limited immediate price impact; any effect would be sentiment-driven and short-lived.

Evidence & confidence

The filing discloses an insider sale price, share count, and post-transaction holdings, but provides no new operational, financial, or regulatory catalyst.

Market effects

Minimal spillover expected; insider-sale Form 4s are common and usually do not reset sector expectations.

None indicated.

None indicated.

Counterpoint

The sale could be for diversification or personal liquidity needs and does not necessarily signal reduced confidence, especially with a small share count.

Key entities

  • Nkarta, Inc.

    Company whose CEO insider sale is disclosed on Form 4.

  • Hastings Paul J

    CEO and director who sold 1,776 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NKTXHighAI 8/10

Nkarta reports safety data for autoimmune cell therapy NKX019

Nkarta Inc. (NKTX) presented safety data for NKX019, its CD19-directed CAR NK cell therapy, in a clinical trial for autoimmune diseases. The data, from 40 patients, showed no serious adverse events. Treatment-emergent adverse events occurred in 85% of patients, with 35% experiencing grade 3 or higher events, primarily hematologic. NKX019 is manufactured from donor-derived NK cells.

$NKTXMedAI 8/10

Nkarta Reports Initial NKX019 Clinical Responses in Myositis and Systemic Sclerosis Trials

Nkarta (NKTX) presented early clinical data for NKX019, showing positive responses in myositis and systemic sclerosis trials. 83% of myositis patients and 86% of systemic sclerosis patients responded to treatment. Safety data from 40 patients showed no serious adverse events. Nkarta plans to evaluate a higher dose and engage with the FDA for potential registration pathways.

$NKTXMedAI 9/10

Nkarta reports early trial data for autoimmune cell therapy

Nkarta Inc. (NKTX) presented early trial data for NKX019, an experimental cell therapy for autoimmune diseases. In trials with 40 patients, 83% of myositis patients and 86% of systemic sclerosis patients showed significant responses. No serious adverse events were reported. Nkarta plans to evaluate higher doses and discuss potential registration pathways with the FDA.

$NKTXLow

Nkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026

Nkarta, Inc. (NKTX) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Nkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026 SOUTH SAN FRANCISCO, Calif., November 6, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineer